Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 06/15 | 06/17 | 53,336 sh | $51.37 | $2,739,870.32 | −3.5% |
Shannon Thyme KlingerChief Legal Officer | ModernaMRNA | Open-market sale10b5-1 plan | 06/04 | 06/08 | 3,471 sh | $50.00 | $173,550 | −4.9% |
Noubar AfeyanDirector | ModernaMRNA | Open-market sale | 05/21 | 05/22 | 9,263 sh | $46.84 | $433,878.92 | −70.2% |
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 05/15 | 05/18 | 53,336 sh | $48.40 | $2,581,462.4 | −3.5% |
Abbas HussainDirector | ModernaMRNA | Open-market sale10b5-1 plan | 05/01 | 05/04 | 5,682 sh | $46.63 | $264,951.66 | −32.0% |
Shannon Thyme KlingerChief Legal Officer | ModernaMRNA | Open-market sale10b5-1 plan | 03/02 | 03/03 | 13,885 sh | $52.29 | $726,046.65 | −18.9% |
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 02/23 | 02/25 | 160,009 sh | $48.84 | $7,814,839.56 | −9.9% |
Noubar AfeyanDirector | ModernaMRNA | Open-market sale | 25/12/11 | 25/12/15 | 23,853 sh | $29.49 | $703,424.97 | −85.9% |
Abbas HussainDirector | ModernaMRNA | Open-market sale10b5-1 plan | 25/12/09 | 25/12/11 | 504 sh | $27.60 | $13,910.4 | −25.0% |
Abbas HussainDirector | ModernaMRNA | Open-market sale10b5-1 plan | 25/06/11 | 25/06/12 | 312 sh | $28.00 | $8,736 | −35.0% |
Paul SaganDirector | ModernaMRNA | Open-market buy | 25/03/03 | 25/03/04 | 31,620 sh | $31.76 | $1,004,251.2 | +11.3% |
CEO | ModernaMRNA | Open-market buy | 25/03/03 | 25/03/04 | 160,314 sh2 trades | $31.22avg. | $5,004,318.13 | +1.8% |
Shannon Thyme KlingerChief Legal Officer | ModernaMRNA | Open-market sale10b5-1 plan | 24/12/09 | 24/12/10 | 529 sh | $44.68 | $23,635.72 | −2.5% |
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 24/12/03 | 24/12/04 | 314 sh | $43.30 | $13,596.2 | −0.0% |
Shannon Thyme KlingerChief Legal Officer | ModernaMRNA | Open-market sale10b5-1 plan | 24/12/03 | 24/12/04 | 112 sh | $43.30 | $4,849.6 | −0.6% |
ModernaMRNA | Open-market sale10b5-1 plan | 24/11/29 | 24/12/02 | 1,420 sh | $42.79 | $60,761.8 | −11.4% | |
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 24/11/29 | 24/12/02 | 291 sh | $42.79 | $12,451.89 | −0.0% |
Shannon Thyme KlingerChief Legal Officer | ModernaMRNA | Open-market sale10b5-1 plan | 24/11/29 | 24/12/02 | 1,418 sh | $42.79 | $60,676.22 | −6.7% |
Stephen HogePresident | ModernaMRNA | Open-market sale10b5-1 plan | 24/11/11 | 24/11/12 | 277 sh | $46.10 | $12,769.7 | −0.0% |
ModernaMRNA | Open-market sale10b5-1 plan | 24/10/07 | 24/10/08 | 715 sh | $60.12 | $42,985.8 | −7.0% |
